(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of 70.24% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Immunome's revenue in 2024 is $12,683,000.On average, 2 Wall Street analysts forecast IMNM's revenue for 2024 to be $510,634,911, with the lowest IMNM revenue forecast at $61,767,934, and the highest IMNM revenue forecast at $959,501,888. On average, 2 Wall Street analysts forecast IMNM's revenue for 2026 to be $914,225,393, with the lowest IMNM revenue forecast at $233,278,897, and the highest IMNM revenue forecast at $1,595,171,889.
In 2027, IMNM is forecast to generate $4,239,798,968 in revenue, with the lowest revenue forecast at $3,184,346,891 and the highest revenue forecast at $5,295,251,044.